Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Ligation for Postpartum Hemorrage (PPH)
Comparison of Serum Anti-Mullerian Hormone Levels Following Uterine Artery Ligation for PPH.
Sponsor: Kanuni Sultan Suleyman Training and Research Hospital
This observational or N/A phase trial investigates Anti-Mullerian Hormone Deficiency and Post Partum Hemorrhage and is currently completed. Kanuni Sultan Suleyman Training and Research Hospital leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
May 2019 — Jan 2021 [monthly]
Completed
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kanuni Sultan Suleyman Training and Research Hospital
For direct contact, visit the study record on ClinicalTrials.gov .